Drug profile · INN
pralsetinib
GAVRETO
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
pralsetinib (GAVRETO) is an FDA-listed pharmaceutical active ingredient. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN pralsetinib
Brand GAVRETO
Route ORAL
Formulation CAPSULE
ATC code L01EX23
Originator RIGEL PHARMACEUTICALS INC
Frequently asked questions
What is pralsetinib?
pralsetinib (GAVRETO) is an FDA-listed pharmaceutical active ingredient. Associated with RIGEL PHARMACEUTICALS INC. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pralsetinib?
GAVRETO is a marketed brand name for pralsetinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pralsetinib?
pralsetinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.